CN111065395A - 用于治疗神经内分泌肿瘤的喹啉衍生物 - Google Patents
用于治疗神经内分泌肿瘤的喹啉衍生物 Download PDFInfo
- Publication number
- CN111065395A CN111065395A CN201880058533.1A CN201880058533A CN111065395A CN 111065395 A CN111065395 A CN 111065395A CN 201880058533 A CN201880058533 A CN 201880058533A CN 111065395 A CN111065395 A CN 111065395A
- Authority
- CN
- China
- Prior art keywords
- acid
- neuroendocrine tumor
- tumor
- compound
- neuroendocrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
具有如下所示的式(I)的用于治疗神经内分泌肿瘤的喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺。还公开了它们在制备用于治疗肿瘤、特别是神经内分泌肿瘤的药物组合物/药剂中的用途。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710833310 | 2017-09-15 | ||
| CN2017108333105 | 2017-09-15 | ||
| PCT/CN2018/105628 WO2019052520A1 (zh) | 2017-09-15 | 2018-09-14 | 用于治疗神经内分泌肿瘤的喹啉衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111065395A true CN111065395A (zh) | 2020-04-24 |
| CN111065395B CN111065395B (zh) | 2021-08-10 |
Family
ID=65723203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880058533.1A Active CN111065395B (zh) | 2017-09-15 | 2018-09-14 | 用于治疗神经内分泌肿瘤的喹啉衍生物 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3682883A4 (zh) |
| CN (1) | CN111065395B (zh) |
| WO (1) | WO2019052520A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015185011A1 (zh) * | 2014-06-06 | 2015-12-10 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
| CN103664892B (zh) | 2010-08-01 | 2015-09-02 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
| CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
-
2018
- 2018-09-14 CN CN201880058533.1A patent/CN111065395B/zh active Active
- 2018-09-14 WO PCT/CN2018/105628 patent/WO2019052520A1/zh unknown
- 2018-09-14 EP EP18855594.0A patent/EP3682883A4/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015185011A1 (zh) * | 2014-06-06 | 2015-12-10 | 正大天晴药业集团股份有限公司 | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 |
| CN105213394A (zh) * | 2014-06-06 | 2016-01-06 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
Non-Patent Citations (4)
| Title |
|---|
| JEAN-YVES SCOAZEC: "Angiogenesis in Neurodocrine Tumors:Therapeutic Applications", 《NEUROENDOCRINOLOGY》 * |
| JOSHUA K. SABARI等: "Relevance of genetic alterations in squamous and small cell lung cancer", 《ANN TRANSL MED》 * |
| M T BARAKAT等: "Neuroendocrine tumours", 《ENDOCRINE-RELATED CANCER》 * |
| YONGKUN SUN等: "Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3682883A1 (en) | 2020-07-22 |
| CN111065395B (zh) | 2021-08-10 |
| WO2019052520A1 (zh) | 2019-03-21 |
| EP3682883A4 (en) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10888559B2 (en) | Quinoline derivatives for non-small cell lung cancer | |
| EP3443962B1 (en) | Quinoline derivative for treating gastric cancer | |
| WO2015185014A1 (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| KR102490547B1 (ko) | 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물 | |
| JP2001240542A (ja) | 肝細胞性腫瘍処置用薬剤 | |
| WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| CN114831988A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| CN111065395B (zh) | 用于治疗神经内分泌肿瘤的喹啉衍生物 | |
| KR20200131265A (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| CN111757737B (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
| CN111110681A (zh) | 喹啉衍生物联合卡培他滨在治疗肝癌的用途 | |
| WO2021104319A1 (zh) | 喹唑啉衍生物或其盐的联用药物组合物及其用途 | |
| WO2023144626A1 (en) | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug | |
| WO2020057539A1 (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| TW202304450A (zh) | 以雄性素受體拮抗劑進行的轉移性去勢抗性前列腺癌患者之治療 | |
| JP2023088898A (ja) | 高リスク転移性ホルモン感受性前立腺がんの治療用の組み合わせ | |
| WO2019223672A1 (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
| WO2009111555A1 (en) | Combination treatment for bladder cancer comprisining valrubicin and trospium chloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |